Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics' stock price has been influenced by financial results, clinical milestones, cash runway extension, stock price fluctuations, arbitration results, and analyst coverage. The company reported its Third Quarter 2025 and Full Year 2025 financial results. 2026 is outlined as a "program-defining year" with multiple clinical readouts expected. The company announced an extension of its cash runway into the first quarter of 2028. The stock experienced a 52-week high of $2.80 on February 26, 2026, and a 52-week low of $0.8621 on May 13, 2025. Allogene Therapeutics reported a favorable result for Servier in an arbitration with Cellectis. Analysts have maintained ratings, with some expecting the stock price to rise.

As a clinical-stage biotechnology company, Allogene Therapeutics does not have commercialized products or services, and therefore, traditional "demand seasonality" for its offerings does not apply. However, February has been the best month for ALLO stock, with an average return of 9.81% and a 63% win rate, while March tends to be the weakest month, averaging an -11.82% return.

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases. The company creates "off-the-shelf" AlloCAR T™ products to overcome the complexities of autologous CAR T therapies. Its pipeline includes Cemacabtagene Ansegedleucel (Cema-Cel) for Large B-Cell Lymphoma (LBCL), ALLO-316 for Renal Cell Carcinoma (RCC), and ALLO-329 for autoimmune diseases (AID).

Allogene Therapeutics' primary operations are based in the United States, with headquarters and R&D facilities in South San Francisco, California, and manufacturing operations in Newark, California. The company conducts multi-center clinical trials across North America, Europe, Australia, and South Korea.

Allogene Therapeutics' brand reputation is shaped by its progress in clinical trials and financial management. Delays in clinical trial milestones and administrative hurdles could negatively affect investor and scientific community perception. Positive clinical trial results and the extension of its cash runway contribute positively to its reputation. The company's focus on developing "off-the-shelf" CAR T therapies positions it as an innovator in the field.

Allogene Therapeutics has a diverse ownership structure. Institutional investors hold a significant portion of the company's stock, ranging from approximately 66.72% to 73.42%. Insider ownership is reported to be between 6.46% and 31.97%, while retail investors hold approximately 1.32% to 41.84% of the shares. Pfizer Inc is the largest individual shareholder, owning 9.04% of the company's shares.